Derived from a 2022 collaboration between the two, Novo Nordisk will partner with Flagship-backed Omega in obesity and Cellarity in NASH. Both programs are in very early stages at present.
Looking to keep its edge in metabolic health, Novo Nordisk A/S is turning to an agreement signed with Flagship Pioneering and its Pioneering Medicines unit to tap into early stage science, specifically in obesity and non-alcoholic steatohepatitis (NASH), through a pair of research collaborations unveiled on 4 January with Omega Therapeutics, Inc. and Cellarity.
The two deals follow an agreement between Novo Nordisk and the venture capital firm two years ago to accelerate research...
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Francesco Hofmann, head of R&D at the mid-sized French group, tells Scrip that its strategy of not playing in the spaces that are dominated by big pharma is paying off.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
